Healthcare | August 17, 2025
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The submission is supported by results from the Phase 3b APEX study
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated
